This is Seriously Bad News For Stocks! – Investment Watch


By Graham Summers, MBA

Stocks are now in very serious trouble.

The ENTIRE collapse thus far in this bear market for stocks has been due to bond yields rising. When Treasuries were yielding 0.25%, investors were willing to pay 20-22 times forward earnings for stocks. However, once Treasury yields rose to 3%+, stocks were repriced down to 16-18 times forward earnings.

The below chart from Ed Yardeni does a great job of illustrating this.

I bring this up because Treasury yields are showing NO SIGNS of stopping.

The yield on the 30-Year Treasury erupted higher last week, breaking above critical resistance at 3.75%. The door is now open to 4% if not 4.25%.

This means that stocks are about to be repriced even lower, possibly to 14 times forward earnings, or ~3,400 on the S&P 500. And if Treasury yields don’t stop soon, we might even go to 12 times forward earnings which is sub-3000 on the S&P 500.

This is Seriously Bad News For Stocks! – Investment Watch

This all ties in with what I’ve been saying for months…

Inflation blew up the Everything Bubble. And smart investors are using this to see incredible returns!



Source link

Related articles

Pump.enjoyable Declares New Upgrades to Creator Charge Mannequin

Pump.enjoyable has acknowledged that there can be adjustments to its creator price mannequin, which triggered a spike within the worth of its native token, PUMP. In keeping with the information by TradingView,...

The Hidden Tradition Dangers Of Fast Progress And How Leaders Can Counter Them

Fast progress — of a staff, division, or firm — is commonly coupled with an underestimation of the cultural...

European inventory markets end the week sturdy

The non-farm payrolls got here in a bit softer than the whisper numbers, giving the "dangerous information is sweet information" crowd a purpose to cheer. For the ECB, it does not change a...

BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Wants, and PROPEL 3 Infigratinib Part 3 Examine Transcript

ObservePlay Earnings NamePlay Earnings Name BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Wants, and PROPEL 3 Infigratinib Part 3 Examine January 9, 2026 8:00 AM EST Firm Contributors Justin ToDaniela...

Anker’s new AeroFit Professional 2 earbuds are already $30 off

We noticed a ton of cool new merchandise at CES 2026, however not all of them made the minimize when it got here to deciding what was better of present. A kind of...
spot_img

Latest articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

WP2Social Auto Publish Powered By : XYZScripts.com